Is the Healthcare Industry Facing a Cleaning Validation Crisis?

Over the past few years, one concern has surfaced repeatedly during visits to pharmaceutical and healthcare manufacturing facilities across Mexico: cleaning processes are becoming increasingly complex, time-consuming, and operationally restrictive.

Manufacturers are facing a paradox. While a production batch may now be completed within a single shift — typically between five and eight hours — the disassembly, cleaning, verification, and release of the equipment can require twice as much time, or even more. In many facilities, cleaning has evolved from a support activity into one of the primary operational bottlenecks.

The inevitable question is: How did we reach this level of scrutiny and control around cleaning processes?

The answer lies in the evolution of modern therapies. Over the last decade, the pharmaceutical industry has seen accelerated development of highly potent compounds, specialized therapies, hormonal treatments, biologics, and monoclonal antibodies. These products deliver significant therapeutic effects at extremely low doses, but they also demand unprecedented levels of contamination control.

As a result, cleaning processes are no longer viewed simply as sanitation procedures. Today, they are critical quality systems that must demonstrate, with scientific evidence, that residues have been reduced to acceptable and validated levels.

A Different Story

Traditionally, laboratory-based cleaning validation has been considered the gold standard for confirming cleanliness. However, the operational reality inside many manufacturing plants tells a different story. Multiple interactions between production and QC laboratories often extend turnaround times considerably. Equipment remains idle while samples are transported, analyzed, reviewed, and approved, delaying batch release and reducing manufacturing efficiency.

For many companies, these delays have become normalized — accepted as part of the process, despite the operational and financial impact they create.

Fortunately, the industry is beginning to adopt more agile and efficient approaches.

One of the most significant shifts is the implementation of at-line and online cleaning verification technologies. This approach moves analytical testing closer to the manufacturing floor, enabling near real-time verification of cleaning processes directly within production environments.

The operational benefits are substantial. Faster analytical response times allow quicker equipment release, reduced downtime, and shorter production cycles. In addition, minimizing sample handling between manufacturing and laboratory areas helps reduce risks associated with human error, sample degradation, or cross-contamination.

Reducing dependency on traditional laboratory workflows also simplifies operations and lowers analytical burden. More importantly, this evolution is not only about speed — it is about improving reliability, consistency, and overall process quality.

Aligning With Broader Initiatives 

At the same time, these strategies align naturally with broader industry initiatives such as Process Analytical Technology (PAT) and Industry 4.0, both of which continue to gain relevance across pharmaceutical and medical device manufacturing operations worldwide.

Naturally, this does not eliminate the need for robust analytical oversight within cleaning validation programs. Rather, it allows manufacturers to eliminate unnecessary bottlenecks while maintaining compliance and strengthening process control.

Several industry organizations and scientific publications have already established the technical foundation supporting the use of Total Organic Carbon (TOC) and Conductivity as viable analytical methods for cleaning verification and residue analysis.

Published studies and industry guidance highlight several important considerations:

• During cleaning processes, active pharmaceutical ingredients are frequently exposed to alkaline or acidic detergents capable of degrading organic molecules. Under these conditions, TOC becomes a highly effective non-specific analytical technique for confirming the removal of product residues, detergents, excipients, and degradation byproducts.

• Comparative studies between traditional HPLC-UV methods and TOC analysis have demonstrated strong recovery performance for both small and large molecules, supporting the reliability of TOC-based approaches.

• Industry references also emphasize that cleaning residues do not necessarily remain chemically unchanged throughout cleaning cycles. Exposure to detergents, water, heat, and air can generate degradation products, making non-specific analytical methods particularly valuable when active ingredients are prone to degradation.

• In multiproduct manufacturing environments, developing compound-specific analytical methods for every active ingredient can become impractical, expensive, and time-intensive. This is one of the primary reasons why non-specific methods such as TOC and Conductivity continue gaining acceptance, especially when monitoring multiple potential residues simultaneously.

Beyond the analytical advantages, several broader industry trends are accelerating the adoption of TOC-based cleaning verification strategies.

First, there is a clear movement toward decentralizing analytical testing. Many companies are implementing at-line and online TOC analysis rather than relying exclusively on centralized QC laboratories. This allows manufacturers to obtain actionable results hours — and sometimes days — earlier than with traditional workflows.

Second, workforce challenges and cost-containment pressures are forcing pharmaceutical companies to operate more efficiently with fewer resources. TOC-based methodologies offer faster analysis, simplified workflows, and lower operational costs while maintaining compliance expectations.

Life-Cycle Approach

At the same time, the industry is increasingly embracing a life-cycle approach to cleaning validation. Rather than performing three validation runs and considering the process complete indefinitely, manufacturers are now expected to continuously monitor and evaluate cleaning performance over time using data-driven methodologies. TOC aligns exceptionally well with this philosophy due to its efficiency, simplicity, and adaptability to ongoing monitoring programs.

Additionally, although many biopharmaceutical manufacturers are incorporating single-use technologies into their production operations, very few facilities operate under fully disposable manufacturing models. As a result, cleaning validation and cleaning verification remain essential components of pharmaceutical manufacturing infrastructure.

Another major driver shaping the future of cleaning validation is the rapid global expansion of GLP-1 drug manufacturing. Companies such as Eli Lilly & CO and Novo Nordisk are investing billions of dollars into new production facilities, focused on peptide-based therapies for obesity and metabolic diseases. Given the nature of these products, TOC-based cleaning validation methodologies are playing a critical role in ensuring manufacturing cleanliness and compliance within these facilities.

Ultimately, pharmaceutical and medical device manufacturers continue to uphold rigorous standards for quality and patient safety while simultaneously seeking ways to improve operational efficiency.

Today, analytical technologies already exist to significantly optimize cleaning verification processes. TOC and Conductivity methodologies provide highly effective tools for quantifying trace levels of organic and inorganic residues respectively, helping manufacturers strengthen cleaning programs while reducing operational inefficiencies.

The industry is no longer asking whether cleaning validation should evolve. The real question is how quickly manufacturers are willing to adopt the tools already available to modernize it.